X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Ryzumvi (phentolamine mesylate) is an alpha adrenergic blocker, which is indicated for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents.
Lead Product(s): Phentolamine Mesylate
Therapeutic Area: Ophthalmology Product Name: Ryzumvi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
The collaboration aims to focus on the ongoing clinical development and commercialization of ACT-246475 (selatogrel), a fast-acting, reversible, and highly selective P2Y12 inhibitor. It is being evaluated for the patients with Acute Myocardial Infarction.
Lead Product(s): Selatogrel
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ACT-246475
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Idorsia Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: $350.0 million
Deal Type: Collaboration March 18, 2024
Details:
The collaboration aims to focus on the ongoing clinical development and commercialization of ACT-246475 (selatogrel), a fast-acting, reversible, and highly selective P2Y12 inhibitor. It is being evaluated for the patients with Acute Myocardial Infarction.
Lead Product(s): Selatogrel
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ACT-246475
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Idorsia Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 27, 2024
Details:
YUPELRI® (revefenacin) inhalation solution is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease.
Lead Product(s): Revefenacin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Yupelri
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
Through the agreement, Viatris divests its rights to women's healthcare products Duphaston (dydrogesterone) and Femoston (estradiol/dydrogesterone) to Theramex.
Lead Product(s): Dydrogesterone
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Duphaston
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Theramex
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Divestment October 10, 2023
Details:
Through the agreement, Viatris divests its rights to women's healthcare products Duphaston (dydrogesterone) and Femoston (sstradiol/dydrogesterone) to Theramex and its Women's Healthcare business, primarily related to oral and injectable contraceptives, to Insud Pharma.
Lead Product(s): Dydrogesterone
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Duphaston
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Theramex
Deal Size: $3,370.0 million Upfront Cash: Undisclosed
Deal Type: Divestment October 01, 2023
Details:
Ryzumvi (phentolamine ophthalmic solution) 0.75% is a preservative-free ophthalmic solution and a nonselective alpha adrenergic antagonist, which is investigated for Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists.
Lead Product(s): Phentolamine Mesylate
Therapeutic Area: Ophthalmology Product Name: Ryzumvi
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Ocuphire Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Details:
The fixed-dose combination of abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg tablets for oral suspension is indicated for the treatment of HIV-1 infection in paediatric patients weighing at least 6 kg.
Lead Product(s): Abacavir,Dolutegravir Sodium,Lamivudine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2023
Details:
Copaxone Depot, a long-acting glatiramer acetate designed to be administered as an intramuscular injection, is being investigated as a once-monthly injection for the treatment of relapsing forms of multiple sclerosis (RMS).
Lead Product(s): Glatiramer Acetate
Therapeutic Area: Neurology Product Name: WhisperJECT
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mapi Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2023
Details:
Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol is the first generic version of AstraZeneca's Symbicort drug-device combination product and is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD).
Lead Product(s): Budesonide,Formoterol Fumarate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Breyna
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
